Search research articles
Contact Us
Filters
Showing results (421-430 of 910) with videos related to
Page
of 91
Sort By:
JAMA Internal Medicine
|
December 9, 2014
Fibrinolysis use among patients requiring interhospital transfer for ST-segment elevation myocardial infarction care: a report from the US National Cardiovascular Data Registry
Amit N Vora, DaJuanicia N Holmes, Ivan Rokos, et al.
Prehospital Emergency Care
|
March 18, 2016
Therapeutic Hypothermia for Patients with Out-of-Hospital Cardiac Arrest in North Carolina
Meena P Rao, Matthew E Dupre, Sean D Pokorney, et al.
Circulation
|
October 9, 2014
Growth differentiation factor 15, a marker of oxidative stress and inflammation, for risk assessment in patients with atrial fibrillation: insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial
Lars Wallentin, Ziad Hijazi, Ulrika Andersson, et al.
European Journal of Internal Medicine
|
February 19, 2026
Major adverse cardiovascular and bleeding outcomes in paroxysmal vs. non-paroxysmal atrial fibrillation: an individual patient-level data analysis of a large cohort of patients from the COMBINE-AF
George Ntaios, Andreas Goette, Michael G Palazzolo, et al.
Circulation
|
August 20, 2003
Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: the COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial
Christopher B Granger, Kenneth W Mahaffey, W Douglas Weaver, et al.
Journal of the American Heart Association
|
December 7, 2021
Efficacy and Safety of Antithrombotic Therapy in Patients With Atrial Fibrillation, Recent Acute Coronary Syndrome, or Percutaneous Coronary Intervention and a History of Heart Failure: Insights From the AUGUSTUS Trial
Marat Fudim, Daniel M Wojdyla, John H Alexander, et al.
Circulation. Cardiovascular Quality and Outcomes
|
February 10, 2011
Mortality implications of primary percutaneous coronary intervention treatment delays: insights from the Assessment of Pexelizumab in Acute Myocardial Infarction trial
Michael P Hudson, Paul W Armstrong, William W O'Neil, et al.
European Heart Journal
|
December 3, 2009
Resolution of ST-segment depression: A new prognostic marker in ST-segment elevation myocardial infarction
Michael C Tjandrawidjaja, Yuling Fu, Cynthia M Westerhout, et al.
Journal of Thrombosis and Thrombolysis
|
June 5, 2013
Warfarin use and long-term outcomes in patients with acute myocardial infarction and atrial fibrillation
James A Nelson, John P Vavalle, Christopher H May, et al.
The American Journal of Cardiology
|
December 26, 2007
International variation in the use of blood transfusion in patients with non-ST-segment elevation acute coronary syndromes
Sunil V Rao, Karen Chiswell, Jie-Lena Sun, et al.
Page
of 91
Search research articles
Search
Showing results (421-430 of 910) with videos related to
Sort By:
Page
of 91
JAMA Internal Medicine
|
December 9, 2014
Fibrinolysis use among patients requiring interhospital transfer for ST-segment elevation myocardial infarction care: a report from the US National Cardiovascular Data Registry
Amit N Vora, DaJuanicia N Holmes, Ivan Rokos, et al.
Prehospital Emergency Care
|
March 18, 2016
Therapeutic Hypothermia for Patients with Out-of-Hospital Cardiac Arrest in North Carolina
Meena P Rao, Matthew E Dupre, Sean D Pokorney, et al.
Circulation
|
October 9, 2014
Growth differentiation factor 15, a marker of oxidative stress and inflammation, for risk assessment in patients with atrial fibrillation: insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial
Lars Wallentin, Ziad Hijazi, Ulrika Andersson, et al.
European Journal of Internal Medicine
|
February 19, 2026
Major adverse cardiovascular and bleeding outcomes in paroxysmal vs. non-paroxysmal atrial fibrillation: an individual patient-level data analysis of a large cohort of patients from the COMBINE-AF
George Ntaios, Andreas Goette, Michael G Palazzolo, et al.
Circulation
|
August 20, 2003
Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: the COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial
Christopher B Granger, Kenneth W Mahaffey, W Douglas Weaver, et al.
Journal of the American Heart Association
|
December 7, 2021
Efficacy and Safety of Antithrombotic Therapy in Patients With Atrial Fibrillation, Recent Acute Coronary Syndrome, or Percutaneous Coronary Intervention and a History of Heart Failure: Insights From the AUGUSTUS Trial
Marat Fudim, Daniel M Wojdyla, John H Alexander, et al.
Circulation. Cardiovascular Quality and Outcomes
|
February 10, 2011
Mortality implications of primary percutaneous coronary intervention treatment delays: insights from the Assessment of Pexelizumab in Acute Myocardial Infarction trial
Michael P Hudson, Paul W Armstrong, William W O'Neil, et al.
European Heart Journal
|
December 3, 2009
Resolution of ST-segment depression: A new prognostic marker in ST-segment elevation myocardial infarction
Michael C Tjandrawidjaja, Yuling Fu, Cynthia M Westerhout, et al.
Journal of Thrombosis and Thrombolysis
|
June 5, 2013
Warfarin use and long-term outcomes in patients with acute myocardial infarction and atrial fibrillation
James A Nelson, John P Vavalle, Christopher H May, et al.
The American Journal of Cardiology
|
December 26, 2007
International variation in the use of blood transfusion in patients with non-ST-segment elevation acute coronary syndromes
Sunil V Rao, Karen Chiswell, Jie-Lena Sun, et al.
Page
of 91